Jun 4, 2019
Two presentations will focus on Antabio’s ANT2681, a novel Metallo β-Lactamase Inhibitor that restores the efficacy of Meropenem against clinical strains of NDM-producing CRE Antabio SAS, a private biopharmaceutical company developing novel antibacterial treatments...
Jan 22, 2019
We are pleased to announce that Antabio’s CEO Marc Lemonnier has been appointed as a new member of the Scientific Advisory Board (SAB) of JPIAMR. The Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) is a global collaborative platform, with 27 nations...
Jul 12, 2018
Labège, France, 12th July 2018. Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today it has extended its Series A financing round with an additional €5.2 million subscribed by investment...
Mar 23, 2018
Antabio announces publication of a manuscript in Antimicrobial Agents and Chemotherapy: Discovery of a Novel Metallo-ß-Lactamase Inhibitor, which can Potentiate Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae Currently available as an ePublication :...
Jan 5, 2018
Labège, France, 05 January 2018. Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, is pleased to announce the addition of four highly successful and accomplished biotech executives to the management...
